Corrective GUSB transfer to the canine mucopolysaccharidosis VII brain

Molecular Therapy

Volumn 22, Issue 4, 2014, Pages 762-773

  Cubizolle, Aurelie ^a,b   Serratrice, Nicolas ^a,b   Skander, Nadia ^a,b   Colle, Marie Anne ^c   Ibanes, Sandy ^a,b   Gennetier, Aurelie ^a,b   Bayo Puxan, Neus ^a,b   Mazouni, Khalil ^a,b   Mennechet, Franck ^a,b   Joussemet, Beatrice ^d   Cherel, Yan ^c   Lajat, Yaouen ^e   Vite, Charles ^f   Bernex, Florence ^b,g   Kalatzis, Vasiliki ^a,b   Haskins, Mark E ^f   Kremer, Eric J ^a,b  

^a INSTITUT DE GÉNÉTIQUE MOLÉCULAIRE DE MONTPELLIER   (France)

^b UNIV MONTPELLIER   (France)

^c LUNAM UNIVERSITÉ   (France)

^d UNIVERSITÉ DE NANTES   (France)

^e NANTES UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g CENTRE VAL D AURELLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; BETA GLUCOSIDASE; GLYCOSAMINOGLYCAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE CASSETTE; GENE THERAPY; GLIA CELL; HIPPOCAMPUS; IMMUNOSUPPRESSIVE TREATMENT; MUCOPOLYSACCHARIDOSIS TYPE 7; NEUROPATHOLOGY; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; TISSUE HOMOGENATE; TROPISM; VIRAL GENE DELIVERY SYSTEM; ANIMAL; BIOSYNTHESIS; BRAIN; DISEASE MODEL; DOG; GENE EXPRESSION REGULATION; GENE TRANSFER; GENETICS; HUMAN; METABOLISM; MOUSE; MUCOPOLYSACCHARIDOSIS VII; PATHOLOGY; VETERINARY;

CANINE ADENOVIRUS; CANIS FAMILIARIS; CHICKEN ANEMIA VIRUS;

ANIMALS; BETA-GLUCOSIDASE; BRAIN; DISEASE MODELS, ANIMAL; DOGS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GLYCOSAMINOGLYCANS; HUMANS; MICE; MUCOPOLYSACCHARIDOSIS VII;

EID: 84897570381     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.283     Document Type: Article

References (52)

1. Mehta, A and Winchester, B (2013). Lysosomal Storage Disorders. Wiley-Blackwell: West Susex, UK. pp. 195
2. Muenzer, J (2011). Overview of the mucopolysaccharidoses. Rheumatology (Oxford) 50 (suppl. 5): V4-12
3. Haskins, ME, Aguirre, GD, Jezyk, PF, Schuchman, EH, Desnick, RJ and Patterson, DF (1991). Mucopolysaccharidosis type VII (Sly syndrome). Beta-glucuronidase-deficient mucopolysaccharidosis in the dog. Am J Pathol 138: 1553-1555
4. Neufeld, EF (2011). From serendipity to therapy. Annu Rev Biochem 80: 1-15
5. Kremer, EJ (2005). Gene transfer to the central nervous system: Current state of the art of the viral vectors. Curr Genomics 6: 13-39
6. Sands, MS and Davidson, BL (2006). Gene therapy for lysosomal storage diseases. Mol Ther 13: 839-849
7. Seregin, SS and Amalfitano, A (2011). Gene therapy for lysosomal storage diseases: Progress, challenges and future prospects. Curr Pharm Des 17: 2558-2574
8. Parenti, G, Pignata, C, Vajro, P and Salerno, M (2013). New strategies for the treatment of lysosomal storage diseases (review). Int J Mol Med 31: 11-20
9. Vite, CH, McGowan, JC, Niogi, SN, Passini, MA, Drobatz, KJ, Haskins, ME et al. (2005). Effective gene therapy for an inherited CNS disease in a large animal model. Ann Neurol 57: 355-364
10. Walton, RM and Wolfe, JH (2007). Abnormalities in neural progenitor cells in a dog model of lysosomal storage disease. J Neuropathol Exp Neurol 66: 760-769
11. Lau, AA, Rozaklis, T, Ibanes, S, Luck, AJ, Beard, H, Hassiotis, S et al. (2012). Helper-dependent canine adenovirus vector-mediated transgene expression in a neurodegenerative lysosomal storage disorder. Gene 491: 53-57
12. Brito, C, Simão, D, Costa, I, Malpique, R, Pereira, CI, Fernandes, P et al. (2012). 3D cultures of human neural progenitor cells: Dopaminergic differentiation and genetic modification. [corrected]. Methods 56: 452-460
13. Henaff, D, Salinas, S and Kremer, EJ (2011). An adenovirus traffic update: From receptor engagement to the nuclear pore. Future Microbiol 6: 179-192
14. Soudais, C, Skander, N and Kremer, EJ (2004). Long-Term in vivo transduction of neurons throughout the rat CNS using novel helper-dependent CAV-2 vectors. FASEB J 18: 391-393
15. Soudais, C, Laplace-Builhe, C, Kissa, K and Kremer, EJ (2001). Preferential transduction of neurons by canine adenovirus vectors and their efficient retrograde transport in vivo. FASEB J 15: 2283-2285
16. Salinas, S, Bilsland, LG, Henaff, D, Weston, AE, Keriel, A, Schiavo, G et al. (2009). CARassociated vesicular transport of an adenovirus in motor neuron axons. PLoS Pathog 5: E1000442
17. Ord, EN, Shirley, R, McClure, JD, McCabe, C, Kremer, EJ, Macrae, IM et al. (2013). Combined antiapoptotic and antioxidant approach to acute neuroprotection for stroke in hypertensive rats. J Cereb Blood Flow Metab 33: 1215-1224
18. Bergelson, JM, Cunningham, JA, Droguett, G, Kurt-Jones, EA, Krithivas, A, Hong, JS et al. (1997). Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275: 1320-1323
19. Salinas, S, Zussy, C, Loustalot, F, Henaff, D, Menendez, G, Morton, PE et al. (2013). Disruption of the coxsackievirus and adenovirus receptor-homodimeric interaction triggers lipid microdomain-And dynamin-dependent endocytosis and lysosomal targeting. J Biol Chem. doi:10.1074/jbc.m113.518365
20. Perreau, M and Kremer, EJ (2005). Frequency, proliferation, and activation of human memory T cells induced by a nonhuman adenovirus. J Virol 79: 14595-14605
21. Perreau, M, Guérin, MC, Drouet, C and Kremer, EJ (2007). Interactions between human plasma components and a xenogenic adenovirus vector: Reduced immunogenicity during gene transfer. Mol Ther 15: 1998-2007
22. Perreau, M, Mennechet, F, Serratrice, N, Glasgow, JN, Curiel, DT, Wodrich, H et al. (2007). Contrasting effects of human, canine, and hybrid adenovirus vectors on the phenotypical and functional maturation of human dendritic cells: Implications for clinical efficacy. J Virol 81: 3272-3284
23. Lee, C, Dineen, TE, Brack, M, Kirsch, JE and Runge, VM (1993). The mucopolysaccharidoses: Characterization by cranial MR imaging. AJNR Am J Neuroradiol 14: 1285-1292
24. Vedolin, L, Schwartz, IV, Komlos, M, Schuch, A, Azevedo, AC, Vieira, T et al. (2007). Brain MRI in mucopolysaccharidosis: Effect of aging and correlation with biochemical findings. Neurology 69: 917-924
25. Sardiello, M, Palmieri, M, di Ronza, A, Medina, DL, Valenza, M, Gennarino, VA et al. (2009). A gene network regulating lysosomal biogenesis and function. Science 325: 473-477
26. Killedar, S, Dirosario, J, Divers, E, Popovich, PG, McCarty, DM and Fu, H (2010). Mucopolysaccharidosis IIIB, a lysosomal storage disease, triggers a pathogenic CNS autoimmune response. J Neuroinflammation 7: 39
27. Begley, DJ, Pontikis, CC and Scarpa, M (2008). Lysosomal storage diseases and the blood-brain barrier. Curr Pharm Des 14: 1566-1580
28. Simonaro, CM, Ge, Y, Eliyahu, E, He, X, Jepsen, KJ and Schuchman, EH (2010). Involvement of the Toll-like receptor 4 pathway and use of TNF-Alpha antagonists for treatment of the mucopolysaccharidoses. Proc Natl Acad Sci USA 107: 222-227
29. Hopwood, JJ (2012). Genetic of lysosomal storage disorders and counselling. In: Mehta, A and Winchester, B (eds). Lysosomal Storage Disorders: A Practical Guide. Wiley-Blackwell: West Sussex, UK. pp. 29-37
30. Walkley, SU (2009). Pathogenic cascades in lysosomal disease-Why so complex? J Inherit Metab Dis 32: 181-189
31. Fernandes, P, Peixoto, C, Santiago, VM, Kremer, EJ, Coroadinha, AS and Alves, PM (2013). Bioprocess development for canine adenovirus type 2 vectors. Gene Ther 20: 353-360
32. Fernandes, P, Santiago, VM, Rodrigues, AF, Tomás, H, Kremer, EJ, Alves, PM et al. (2013). Impact of E1 and Cre on adenovirus vector amplification: Developing MDCK CAV-2-E1 and E1-Cre transcomplementing cell lines. PLoS ONE 8: E60342
33. Ariza, L, Giménez-Llort, L, Cubizolle, A, Pagès, G, García Lareu, B, Serratrice, N et al. (2013). CNS delivery of helper-dependent canine adenovirus corrects neuropathology and behavior in mucopolysaccharidosis type vii mice. Hum Gene Ther. doi:10.1089/ hum2013.152
34. Bru, T, Salinas, S and Kremer, EJ (2010). An update on canine adenovirus type 2 and its vectors. Viruses 2: 2134-2153
35. Schoehn, G, El Bakkouri, M, Fabry, CM, Billet, O, Estrozi, LF, Le, L et al. (2008). Three-dimensional structure of canine adenovirus serotype 2 capsid. J Virol 82: 3192-3203
36. Lieberman, DM, Laske, DW, Morrison, PF, Bankiewicz, KS and Oldfield, EH (1995). Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg 82: 1021-1029
37. Alba, R, Bosch, A and Chillon, M (2005). Gutless adenovirus: Last-generation adenovirus for gene therapy. Gene Ther 12 (suppl. 1): S18-S27
38. Amalfitano, A and Parks, RJ (2002). Separating fact from fiction: Assessing the potential of modified adenovirus vectors for use in human gene therapy. Curr Gene Ther 2: 111-133
39. Chevalier, G, Suberbielle, E, Monnet, C, Duplan, V, Martin-Blondel, G, Farrugia, F et al. (2011). Neurons are MHC class I-dependent targets for CD8 T cells upon neurotropic viral infection. PLoS Pathog 7: E1002393
40. Piersanti, S, Astrologo, L, Licursi, V, Costa, R, Roncaglia, E, Gennetier, A et al. (2013). Differentiated neuroprogenitor cells incubated with human or canine adenovirus, or lentiviral vectors have distinct transcriptome profiles. PLoS ONE 8: E69808
41. Ellinwood, NM, Ausseil, J, Desmaris, N, Bigou, S, Liu, S, Jens, JK et al. (2011). Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes. Mol Ther 19: 251-259
42. Vogler, C, Galvin, N, Levy, B, Grubb, J, Jiang, J, Zhou, XY et al. (2003). Transgene produces massive overexpression of human beta-glucuronidase in mice, lysosomal storage of enzyme, and strain-dependent tumors. Proc Natl Acad Sci USA 100: 2669-2673
43. Frisella, WA, O'Connor, LH, Vogler, CA, Roberts, M, Walkley, S, Levy, B et al. (2001). Intracranial injection of recombinant adeno-Associated virus improves cognitive function in a murine model of mucopolysaccharidosis type VII. Mol Ther 3: 351-358
44. Stein, CS, Ghodsi, A, Derksen, T and Davidson, BL (1999). Systemic and central nervous system correction of lysosomal storage in mucopolysaccharidosis type VII mice. J Virol 73: 3424-3429
45. Smith, RL, Traul, DL, Schaack, J, Clayton, GH, Staley, KJ and Wilcox, CL (2000). Characterization of promoter function and cell-Type-specific expression from viral vectors in the nervous system. J Virol 74: 11254-11261
46. Orii, KO, Grubb, JH, Vogler, C, Levy, B, Tan, Y, Markova, K et al. (2005). Defining the pathway for Tat-mediated delivery of beta-glucuronidase in cultured cells and MPS VII mice. Mol Ther 12: 345-352
47. Tomatsu, S, Orii, KO, Vogler, C, Grubb, JH, Snella, EM, Gutierrez, M et al. (2003). Production of MPS VII mouse (Gus(tm(hE540A x mE536A)Sly)) doubly tolerant to human and mouse beta-glucuronidase. Hum Mol Genet 12: 961-973
48. Seok, J, Warren, HS, Cuenca, AG, Mindrinos, MN, Baker, HV, Xu, W et al.; Inflammation and Host Response to Injury, Large Scale Collaborative Research Program. (2013). Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 110: 3507-3512
49. Heuer, GG, Passini, MA, Jiang, K, Parente, MK, Lee, VM, Trojanowski, JQ et al. (2002). Selective neurodegeneration in murine mucopolysaccharidosis VII is progressive and reversible. Ann Neurol 52: 762-770
50. Walkley, SU, Sikora, J, Micsenyi, M, Davidson, C and Dobrenis, K (2010). Lysosomal compromise and brain dysfunction: Examining the role of neuroaxonal dystrophy. Biochem Soc Trans 38: 1436-1441
51. Vitner, EB, Platt, FM and Futerman, AH (2010). Common and uncommon pathogenic cascades in lysosomal storage diseases. J Biol Chem 285: 20423-20427
52. Bosch, A, Perret, E, Desmaris, N and Heard, JM (2000). Long-Term and significant correction of brain lesions in adult mucopolysaccharidosis type VII mice using recombinant AAV vectors. Mol Ther 1: 63-70.